Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/6/2025 | $57.00 | Buy | H.C. Wainwright |
| 12/4/2024 | $73.00 → $69.00 | Buy | B. Riley Securities |
| 4/11/2024 | $24.00 | Buy | Craig Hallum |
| 9/8/2022 | $17.00 | Buy | B. Riley Securities |
| 10/14/2021 | $16.00 | Buy | B. Riley Securities |
| 9/24/2021 | $15.00 | Buy | Aegis Capital |
| 7/2/2021 | $14.25 | Buy | Ladenburg Thalmann |
10-Q - HARROW, INC. (0001360214) (Filer)
8-K - HARROW, INC. (0001360214) (Filer)
DEFA14A - HARROW, INC. (0001360214) (Filer)
Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, today announced that Amir H. Shojaei, PharmD, PhD, has joined Harrow as Chief Scientific Officer (CSO). With a remarkable career spanning 28 years in life sciences, Dr. Shojaei brings deep expertise in clinical development, regulatory affairs, and the commercialization of biopharmaceutical and biologic products, including groundbreaking work in anterior and posterior segment ophthalmic indications. Dr. Shojaei most recently served as CSO and Executive Vice President of Clinical Development at AsclepiX Therapeutics, where he spearheaded the development of innovative therapies for neovascular retinal disorders. P
Harrow (NASDAQ:HROW), a leading U.S. eyecare pharmaceutical company, is pleased to announce the appointment of Greg DiPasquale as Senior Vice President, Head of Commercial, effective immediately. DiPasquale will oversee sales, marketing, and sales operations for Harrow's rapidly growing portfolio of branded ophthalmic products. This new role reflects Harrow's commitment to enhancing its leadership structure to support the Company's continued growth. John Saharek, Harrow's Chief Commercial Officer and Chief Executive Officer of ImprimisRx, will continue to oversee Harrow's commercial business, focusing on the day-to-day management of Harrow's market‑leading compounded division. DiPasquale
Harrow (NASDAQ:HROW), a leading U.S. eyecare pharmaceutical company, today announced the appointment of Mark Mannebach, Ph.D., R.Ph. as Head of Regulatory Affairs and Pharmacovigilance, responsible for overseeing and managing all regulatory related submissions and strategy related to the Company's portfolio of new and existing products. Dr. Mannebach's successful 30-year career in the pharmaceutical industry, much of which was focused in ophthalmology, includes leadership roles in regulatory affairs, quality assurance, program management and pharmaceutical product development. "Dr. Mannebach brings to Harrow decades of regulatory and clinical expertise and leadership –specifically in ophth
First-Quarter 2025 and Recent Selected Highlights: Revenues of $47.8 million, a 38% increase over $34.6 million recorded in prior-year period VEVYE revenues increased to $21.5 million, a 35% increase from $16.0 million in the fourth quarter 2024 Cash flow from operations reached a record high of $19.7 million GAAP net loss of $(17.8) million Adjusted EBITDA of $(2.0) million Cash and cash equivalents of $66.7 million as of March 31, 2025 VEVYE® Access for All launch in mid-March is accelerating market share capture and revenue growth Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, announced results for the first quarter ended March 31, 2025. Th
Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on May 9, 2025 Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, today announced that it will report its financial results for the first quarter ended March 31, 2025, on Thursday, May 8, 2025, after the market close. The Company will also post its first quarter Letter to Stockholders to the "Investors" section of its website, harrow.com. Harrow will host a conference call and live webcast at 8:00 a.m. Eastern Time on Friday, May 9, 2025, to discuss the results and provide a business update. Conference Call Information Participants can access the live conference call via webcast on th
Fourth-Quarter, Full-Year 2024, and Recent Highlights: Record revenues of $66.8 million for Q4 2024, an 84% increase over Q4 2023 Revenues of $199.6 million for FY 2024, a 53% increase over FY 2023 GAAP net income of $6.8 million for Q4 2024, for a GAAP net loss of $(17.5) million for FY 2024 Adjusted EBITDA of $22.5 million for Q4 2024, leading to Adjusted EBITDA of $40.3 million for FY 2024 IHEEZO® unit demand and VEVYE® prescriptions for Q4 2024 each increased over 40% over Q3 2024 VEVYE® Access for All program expected to drive continued market share expansion in 2025 TRIESENCE® transitional pass-through approved, significantly increasing addressable market opportunity H
4 - HARROW, INC. (0001360214) (Issuer)
4 - HARROW, INC. (0001360214) (Issuer)
4/A - HARROW, INC. (0001360214) (Issuer)
H.C. Wainwright initiated coverage of Harrow with a rating of Buy and set a new price target of $57.00
B. Riley Securities reiterated coverage of Harrow with a rating of Buy and set a new price target of $69.00 from $73.00 previously
Craig Hallum initiated coverage of Harrow with a rating of Buy and set a new price target of $24.00
4 - HARROW, INC. (0001360214) (Issuer)
4 - HARROW, INC. (0001360214) (Issuer)
4 - HARROW, INC. (0001360214) (Issuer)
Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, today announced that management will participate in the following two investor conferences in May: B. Riley Securities 25th Annual Investor Conference (The Ritz-Carlton, Marina del Rey, CA) Format: Fireside Chat, followed by 1x1 Investor Meetings Date/Time: Wednesday, May 21, 2025, through Thursday, May 22, 2025 Craig-Hallum 22nd Annual Institutional Investor Conference (Depot Renaissance Hotel, Minneapolis, MN) Format: 1x1 and Small Group Investor Meetings Date/Time: Wednesday, May 28, 2025 Investors interested in meeting with management during either conference should contact their B. Riley or Craig-Hallum r
First-Quarter 2025 and Recent Selected Highlights: Revenues of $47.8 million, a 38% increase over $34.6 million recorded in prior-year period VEVYE revenues increased to $21.5 million, a 35% increase from $16.0 million in the fourth quarter 2024 Cash flow from operations reached a record high of $19.7 million GAAP net loss of $(17.8) million Adjusted EBITDA of $(2.0) million Cash and cash equivalents of $66.7 million as of March 31, 2025 VEVYE® Access for All launch in mid-March is accelerating market share capture and revenue growth Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, announced results for the first quarter ended March 31, 2025. Th
Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on May 9, 2025 Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, today announced that it will report its financial results for the first quarter ended March 31, 2025, on Thursday, May 8, 2025, after the market close. The Company will also post its first quarter Letter to Stockholders to the "Investors" section of its website, harrow.com. Harrow will host a conference call and live webcast at 8:00 a.m. Eastern Time on Friday, May 9, 2025, to discuss the results and provide a business update. Conference Call Information Participants can access the live conference call via webcast on th
SC 13G/A - HARROW, INC. (0001360214) (Subject)
SC 13G/A - HARROW, INC. (0001360214) (Subject)
SC 13G/A - HARROW, INC. (0001360214) (Subject)